Atlas Brown Inc. Increases Stake in Organon & Co. (NYSE:OGN)

Atlas Brown Inc. raised its holdings in shares of Organon & Co. (NYSE:OGN) by 21.5% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 35,357 shares of the company’s stock after acquiring an additional 6,253 shares during the quarter. Atlas Brown Inc.’s holdings in Organon & Co. were worth $528,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other hedge funds have also recently modified their holdings of the company. Wealth Enhancement Advisory Services LLC lifted its position in Organon & Co. by 3.0% during the fourth quarter. Wealth Enhancement Advisory Services LLC now owns 44,144 shares of the company’s stock valued at $659,000 after purchasing an additional 1,284 shares in the last quarter. Range Financial Group LLC bought a new position in shares of Organon & Co. in the fourth quarter worth about $827,000. CWA Asset Management Group LLC grew its stake in shares of Organon & Co. by 27.0% during the 4th quarter. CWA Asset Management Group LLC now owns 23,596 shares of the company’s stock valued at $352,000 after acquiring an additional 5,017 shares during the period. Versant Capital Management Inc grew its stake in shares of Organon & Co. by 92.2% during the 4th quarter. Versant Capital Management Inc now owns 2,760 shares of the company’s stock valued at $41,000 after acquiring an additional 1,324 shares during the period. Finally, Garden State Investment Advisory Services LLC bought a new stake in Organon & Co. during the 3rd quarter worth approximately $203,000. Institutional investors own 77.43% of the company’s stock.

Analysts Set New Price Targets

Separately, Evercore ISI raised shares of Organon & Co. to a “strong-buy” rating in a research note on Wednesday, September 18th.

Organon & Co. Price Performance

NYSE OGN remained flat at $16.00 during trading hours on Friday. The company had a trading volume of 3,097,837 shares, compared to its average volume of 2,953,566. The company has a quick ratio of 1.21, a current ratio of 1.70 and a debt-to-equity ratio of 17.73. Organon & Co. has a one year low of $13.87 and a one year high of $23.10. The business’s 50-day moving average is $15.41 and its 200-day moving average is $18.44. The stock has a market cap of $4.12 billion, a P/E ratio of 3.17, a price-to-earnings-growth ratio of 0.81 and a beta of 0.76.

Organon & Co. (NYSE:OGN) last released its quarterly earnings data on Thursday, October 31st. The company reported $0.87 EPS for the quarter, missing the consensus estimate of $0.90 by ($0.03). The company had revenue of $1.58 billion for the quarter, compared to the consensus estimate of $1.56 billion. Organon & Co. had a net margin of 20.30% and a return on equity of 644.70%. The firm’s revenue for the quarter was up 4.1% on a year-over-year basis. During the same period last year, the company earned $0.78 EPS. Equities research analysts anticipate that Organon & Co. will post 3.89 EPS for the current fiscal year.

Organon & Co. Announces Dividend

The firm also recently announced a quarterly dividend, which was paid on Thursday, December 12th. Investors of record on Tuesday, November 12th were issued a $0.28 dividend. This represents a $1.12 dividend on an annualized basis and a dividend yield of 7.00%. The ex-dividend date was Tuesday, November 12th. Organon & Co.’s dividend payout ratio (DPR) is presently 22.22%.

Organon & Co. Company Profile

Organon & Co develops and delivers health solutions through a portfolio of prescription therapies and medical devices within women's health in the United States and internationally. Its women's health portfolio comprises contraception and fertility brands, such as Nexplanon, a long-acting reversible contraceptive; NuvaRing, a monthly vaginal contraceptive ring; Cerazette, a daily pill used to prevent pregnancy; Marvelon, progestin and estrogen used as daily pills to prevent pregnancy; Follistim AQ, used to promote the development of multiple ovarian follicles in assisted reproduction technology procedures; Elonva, an ovarian follicle stimulant; Ganirelix Acetate Injection, an injectable antagonist; and Jada, for abnormal postpartum uterine bleeding or hemorrhage.